Drugs / Crenezumab
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02427243 | Apr → Jul 2015 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02353598 | Feb 2015 → Nov 2016 | Alzheimer disease | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00997919 | Oct 2009 → Feb 2010 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00736775 | Aug 2008 → May 2010 | Alzheimer disease | Genentech, Inc. | Completed | No outcome recorded |
| Phase 25 trials · 3 missed | ||||||
| Phase 2 | NCT03977584 | Jun 2019 → Apr 2022 | Alzheimer disease | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT01998841 | Dec 2013 → Mar 2022 | Alzheimer disease | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT01723826 | Dec 2012 → Feb 2017 | Alzheimer disease | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01397578 | Aug 2011 → Apr 2014 | Alzheimer disease | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT01343966 | Apr 2011 → Feb 2014 | Alzheimer disease | Genentech, Inc. | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT03491150 | Apr 2018 → May 2019 | Alzheimer disease | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT03114657 | Mar 2017 → Jun 2019 | Alzheimer disease | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT02670083 | Mar 2016 → May 2019 | Alzheimer disease | Hoffmann-La Roche | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2022-08-02 | AC Immune SA | Results Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC acimmune.com ↗
As previously reported on June 16, 2022 , the trial did not meet its co-primary endpoints (API ADAD composite cognitive total score and the Free and Cued Selective Reminding Test Cueing Index). |
| 2022-06-16 | Hoffmann-La Roche | Results Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease roche.com ↗
The trial did not demonstrate a statistically significant clinical benefit in either of its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function, measured by the API ADAD composite cognitive score and the Free and Cued Selective Reminding Test (FCSRT) Cueing Index, respectively. |
| 2022-06-16 | AC Immune SA | Results AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease acimmune.com ↗
Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease |
| 2022-06-15 | Genentech, Inc. | Results Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease gene.com ↗
The trial did not demonstrate a statistically significant clinical benefit in either of its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function, measured by the API ADAD composite cognitive score and the Free and Cued Selective Reminding Test (FCSRT) Cueing Index, respectively. |
| 2019-01-30 | Hoffmann-La Roche | Results Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) - other company programmes in AD continue roche.com ↗
No safety signals for crenezumab were observed in this analysis and the overall safety profile was similar to that seen in previous trials. |
| 2019-01-29 | Genentech, Inc. | Results Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer’s Disease (AD) - Other Company Programs in AD Continue gene.com ↗ |
| 2018-07-19 | Genentech, Inc. | Results Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC) gene.com ↗
Late-breaking Phase II exploratory analysis of investigational crenezumab to show impact on beta amyloid oligomer levels in cerebral spinal fluid (CSF) |
| 2016-12-09 | AC Immune SA | Results AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB acimmune.com ↗
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that its partner Genentech, member of Roche group, has presented important data to support the unique binding and increased dosing of its Alzheimer's therapy on crenezumab, an anti-Abeta antibody. |
All press releases naming this drug 9 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Crenezumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02670083 ↗ |
| Known as | MABT5102A | “Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage” NCT00736775 ↗ |
| Known as | RG-7412 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743004 ↗ |
| Action | Inhibit | “Amyloid-beta A4 protein inhibitor” CHEMBL1743004 ↗1“Anti-Abeta (MABT5102A)” NCT00736775 ↗ |
| Modality | Monoclonal antibody | “crenezumab, a fully humanized anti-beta-amyloid (Aβ) immunoglobulin G4 (IgG4) monoclonal antibody” PMID 31969177 ↗ Jan 2020 |
| Route | Intravenous | “Intravenous single and multiple doses” NCT00736775 ↗ |
| Target | APP | “Amyloid-beta A4 protein inhibitor” CHEMBL1743004 ↗ |